Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed (Arm A) versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab (Arm B) in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Zinner, Ralph
Ross, Helen J.
Weaver, Robert
Govindan, Ramaswamy
Holden, Viran R.
Chowhan, Naveed Mahfooz
Beck, J. Thaddeus
Waterhouse, David Michael
Modiano, Manuel
Rao, Vijay Phooshkooru
Liu, Jingyi
Koustenis, Andrew
Melemed, Symantha
Guba, Susan C.
Ortuzar, Waldo Feliu
Desaiah, Durisala
Spigel, David R.
Obasaju, Coleman K.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Mayo Clin, Scottsdale, AZ USA
[3] Florida Canc Specialists, Tampa, FL USA
[4] Washington Univ, Sch Med St Louis, St Louis, MO USA
[5] St Johns Clin, Springfield, MO USA
[6] Canc Care Ctr Inc, New Albany, IN USA
[7] Highlands Oncol Grp, Fayetteville, AR USA
[8] Oncol Hematol Care SCRI, Cincinnati, OH USA
[9] Arizona Clin Res Ctr, Tucson, AZ USA
[10] Arizona Oncol, Tucson, AZ USA
[11] Mid Dakota Clin, Bismarck, ND USA
[12] Eli Lilly & Co, Indianapolis, IN 46285 USA
[13] Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA8003
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
    Zinner, Ralph
    Ross, Helen J.
    Weaver, Robert
    Govindan, Ramaswamy
    Holden, Viran R.
    Chowhan, Naveed Mahfooz
    Beck, J. Thaddeus
    Waterhouse, David Michael
    Modiano, Manuel
    Rao, Vijay Phooshkooru
    Liu, Jingyi
    Koustenis, Andrew
    Melemed, Symantha
    Guba, Susan C.
    Ortuzar, Waldo Feliu
    Desaiah, Durisala
    Spigel, David R.
    Obasaju, Coleman K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [2] PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin plus Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Zinner, Ralph G.
    Obasaju, Coleman K.
    Spigel, David R.
    Weaver, Robert W.
    Beck, J. Thaddeus
    Waterhouse, David M.
    Modiano, Manuel R.
    Hrinczenko, Borys
    Nikolinakos, Petros G.
    Liu, Jingyi
    Koustenis, Andrew G.
    Winfree, Katherine B.
    Melemed, Symantha A.
    Guba, Susan C.
    Ortuzar, Waldo I.
    Desaiah, Durisala
    Treat, Joseph A.
    Govindan, Ramaswamy
    Ross, Helen J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (01) : 134 - 142
  • [3] PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
    Patel, Jyoti D.
    Socinski, Mark A.
    Garon, Edward B.
    Reynolds, Craig H.
    Spigel, David R.
    Olsen, Mark R.
    Hermann, Robert C.
    Jotte, Robert M.
    Beck, Thaddeus
    Richards, Donald A.
    Guba, Susan C.
    Liu, Jingyi
    Frimodt-Moller, Bente
    John, William J.
    Obasaju, Coleman K.
    Pennella, Eduardo J.
    Bonomi, Philip
    Govindan, Ramaswamy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (34) : 4349 - U77
  • [4] Randomized, open-label study of pemetrexed/carboplatin followed by maintenance pemetremexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevaciztimab in patients with advanced non-small cell lung cancer (NSCLC) of nonsquamous histology
    Zinner, R.
    Saxman, S.
    Peng, G.
    Ortuzar, W. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] EXPLORATORY SUBSET ANALYSIS IN AFRICAN AMERICANS FROM THE POINTBREAK STUDY (RANDOMIZED PHASE 3 PEMETREXED plus CARBOPLATIN plus BEVACIZUMAB FOLLOWED BY MAINTENANCE PEMETREXED plus BEVACIZUMAB VERSUS PACLITAXEL plus CARBOPLATIN plus BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB IN PATIENTS WITH STAGE IIIB/IV NONSQUAMOUS NON-SMALL CELL LUNG CANCER)
    Reynolds, Craig
    Patel, Jyoti D.
    Garon, Edward
    Olsen, Mark R.
    Bonomi, Philip
    Govindan, Ramaswamy
    Obasaju, Coleman
    Pennella, Eduardo J.
    Liu, Jingyi
    Guba, Susan C.
    Spigel, David
    Hermann, Robert C.
    Socinski, Mark A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S562 - S562
  • [6] Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
    Patel, Jyoti D.
    Bonomi, Philip
    Socinski, Mark A.
    Govindan, Ramaswamy
    Hong, Shengyan
    Obasaju, Coleman
    Pennella, Eduardo J.
    Girvan, Allicia C.
    Guba, Susan C.
    [J]. CLINICAL LUNG CANCER, 2009, 10 (04) : 252 - 256
  • [7] Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non-Small-Cell Lung Cancer of Nonsquamous Histology
    Zinner, Ralph G.
    Saxman, Scott B.
    Peng, Guangbin
    Monberg, Matthew J.
    Ortuzar, Waldo I.
    [J]. CLINICAL LUNG CANCER, 2010, 11 (05) : 352 - 357
  • [8] Randomized phase II study of pemetrexed plus carboplatin followed by pemetrexed versus paclitaxel plus carboplatin followed by pemetrexed in advanced nonsquamous, non-small cell lung cancer (LOGIK 0904)
    Takayama, Koichi
    Inoue, Koji
    Takeshita, Masafumi
    Tashiro, Naoki
    Harada, Taishi
    Seto, Takashi
    Imanaga, Tomotoshi
    Fujimoto, Noriko
    Nakagaki, Noriaki
    Kawasaki, Masayuki
    Kishimoto, Junji
    Ichinose, Yukito
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab for Japanese nonsquamous non-small cell lung cancer
    Yokoi, Takashi
    Torii, Yoshitaro
    Katashiba, Yuichi
    Sugimoto, Hiroyuki
    Hayashi, Mina
    Shimizu, Toshiki
    Nomura, Shosaku
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
    Spigel, David R.
    Patel, Jyoti D.
    Reynolds, Craig H.
    Garon, Edward B.
    Hermann, Robert C.
    Govindan, Ramaswamy
    Olsen, Mark R.
    Winfree, Katherine B.
    Chen, Jian
    Liu, Jingyi
    Guba, Susan C.
    Socinski, Mark A.
    Bonomi, Philip
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 353 - 359
12345